Reusable Face Masks to Reduce Risk of Viral Respiratory Infections and Asthma Exacerbations
Launched by QUEEN MARY UNIVERSITY OF LONDON · Mar 18, 2025
Trial Information
Current as of May 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The REMASK trial is a study that aims to find out if providing free reusable face masks can help reduce the risk of viral respiratory infections, like colds or flu, and asthma flare-ups in adults with asthma and their household members. This research is part of a larger project called the COVIDENCE UK study, which is looking at how COVID-19 affects people over time. The trial is not yet recruiting participants, but it will include adults aged 16 and older who have a confirmed diagnosis of asthma and are currently receiving treatment for it.
To participate, individuals must be involved in the COVIDENCE UK nasal swab study and live with someone who is also taking part in the trial. However, those who regularly wear certain high-protection masks in public, live with children, or share a home with other asthma participants from the study may not be eligible. Participants can expect to receive a reusable face mask and will help researchers understand if wearing the mask can improve their health by reducing infections and asthma symptoms.
Gender
ALL
Eligibility criteria
- Eligibility criteria, participants with asthma ('index participants'):
- Inclusion Criteria:
- • Aged 16 or more years
- • Doctor diagnosis of asthma
- • Current prescription for treatment of asthma
- • Participant in COVIDENCE UK nasal swab study
- Exclusion Criteria:
- • Regularly using any FFP-rated face mask when in an indoor public place
- • Currently sharing household with one or more children
- • Currently sharing household with one or more other COVIDENCE UK participants who have asthma
- • Unable to tolerate wearing face mask
- Eligibility criteria, household members of index participants:
- • Inclusion criteria
- • Age 16 or more
- • Living in same household as index participant who has consented to take part in trial
- • Exclusion criteria
- • - Unable to tolerate wearing face mask
About Queen Mary University Of London
Queen Mary University of London is a prestigious research-intensive institution recognized for its commitment to advancing medical science and improving health outcomes. As a leading sponsor of clinical trials, the university harnesses its academic excellence and innovative research capabilities to explore groundbreaking treatments and therapies across various medical disciplines. With a focus on collaboration, the institution engages with a diverse network of clinicians, researchers, and industry partners to ensure rigorous study design, ethical conduct, and the translation of research findings into clinical practice. Queen Mary University of London is dedicated to contributing to the global body of knowledge in healthcare through high-quality clinical research that prioritizes patient safety and welfare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Greater London, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported